Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA

Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral...